Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Axillary lymphoscintigraphy in the management of patients with breast cancer: A study of 341 patients

Conference · · J. Nucl. Med.; (United States)
OSTI ID:5939096
Axillary lymphoscintigraph (AxLS) has been proposed preoperatively to diagnose breast cancer and postoperatively to predict recurrence; its role in routine management of carcinoma of the breast has not yet been determined. In a population with predominantly Stage I or II disease AxLS was performed in 140 patients who underwent surgery without axillary dissection (GpI), and in 201 whose surgery included axillary dissection (GpII), 49 of whom were studied prior to surgery; 84% of all patients were studied within 2 months of operation. Bilateral interdigital injections of Tc-99mSb/sub 2/S/sub 3/ (20MBq) were given and anterior images obtained 2 hours later. Internal mammary lymphoscintigraphy (IMLS) was performed concurrently. Scans were classed as normal (NOR) or abnormal (ABN) by adapting criteria used in interpretation of IMLS. For analysis of prognostic value, only patients with a minimum follow-up of 2 years were assessed. In patients scanned prior to surgery, AxLS sensitivity and specificity in predicting nodal involvement were 74% and 77% respectively. Clinical correlation suggests that features in the AxLS can be recognized which may be predictive of disease outcome despite the lack of direct correlation between the image and histopathological findings.
Research Organization:
The Princess Margaret Hospital, Toronto
OSTI ID:
5939096
Report Number(s):
CONF-850611-
Conference Information:
Journal Name: J. Nucl. Med.; (United States) Journal Volume: 26:5
Country of Publication:
United States
Language:
English